[go: up one dir, main page]

PE20020603A1 - Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy) - Google Patents

Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)

Info

Publication number
PE20020603A1
PE20020603A1 PE2001001110A PE2001001110A PE20020603A1 PE 20020603 A1 PE20020603 A1 PE 20020603A1 PE 2001001110 A PE2001001110 A PE 2001001110A PE 2001001110 A PE2001001110 A PE 2001001110A PE 20020603 A1 PE20020603 A1 PE 20020603A1
Authority
PE
Peru
Prior art keywords
npy
neuropeptide
receptor
pyrimidine
alkyl
Prior art date
Application number
PE2001001110A
Other languages
English (en)
Inventor
Volker Breu
Frank Dautzenberg
Patrizio Mattei
Philippe Pflieger
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020603A1 publication Critical patent/PE20020603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIMIDINA DE FORMULA I DONDE R1 Y R2 SON ALQUILO, CICLOALQUILO, ARALQUILO O UNO DE R1 Y R2 ES H Y EL OTRO ES ALQUILO, AMINOALQUILO O CICLOPROPILO; R1 Y R2 JUNTO A N FORMAN UN ANILLO HETEROCICLICO DE 4 A 10 MIEMBROS; R3 ES ALQUILO CICLOALQUILO, ALCOXIALQUILO, HIDROXIALQUILO, HAL0ALQUILO, ALCOXILO, ALCOXIALQUILO, ENTRE OTROS; R4 ES ARILO, HETEROARILO DONDE R4 NO ES NITROFURILO O NITROTIENILO; A1 Y A2 SON CH, N. SON COMPUESTOS PREFERIDOS (E)-4-METIL-6-PIRROLIDIN-1-IL-2-[2-(3-TRIFLUOROMETIL-FENIL)-VINIL]-PIRIMIDINA, (E)-2-[2-(2,4-DICLORO-FENIL)-VINIL]-4-METIL-6-PIRROLIDIN-1-IL-PIRIMIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION Y UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DEL NEUROPEPTIDO Y (NPY) Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, DIABETES, OBESIDAD
PE2001001110A 2000-11-10 2001-11-08 Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy) PE20020603A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00124610 2000-11-10

Publications (1)

Publication Number Publication Date
PE20020603A1 true PE20020603A1 (es) 2002-07-20

Family

ID=8170342

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001110A PE20020603A1 (es) 2000-11-10 2001-11-08 Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)

Country Status (20)

Country Link
US (1) US6657060B2 (es)
EP (1) EP1335906B1 (es)
JP (1) JP2004524279A (es)
KR (1) KR100611853B1 (es)
CN (1) CN1473156A (es)
AR (1) AR034700A1 (es)
AT (1) ATE340784T1 (es)
AU (2) AU2790502A (es)
BR (1) BR0115045A (es)
CA (1) CA2427350A1 (es)
DE (1) DE60123458T2 (es)
DK (1) DK1335906T3 (es)
ES (1) ES2271100T3 (es)
MX (1) MXPA03004136A (es)
PA (1) PA8531701A1 (es)
PE (1) PE20020603A1 (es)
PT (1) PT1335906E (es)
UY (1) UY27018A1 (es)
WO (1) WO2002038551A1 (es)
ZA (1) ZA200302970B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7768604B2 (en) * 2005-09-20 2010-08-03 Au Optronics Corporation Transflective liquid crystal display with partially shifted reflectivity curve
EP1979325A1 (en) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
JP2010501537A (ja) * 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101796048A (zh) * 2007-07-09 2010-08-04 阿斯利康(瑞典)有限公司 用于治疗增殖病症的三取代的嘧啶衍生物
US20100227858A1 (en) * 2007-07-09 2010-09-09 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EA018708B1 (ru) 2007-07-09 2013-10-30 Астразенека Аб ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
CA2692945A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
US20110166135A1 (en) * 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
WO2011112428A2 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720467B2 (ja) * 1988-06-15 1995-03-08 松下電器産業株式会社 超音波診断装置
JPH024345A (ja) * 1988-06-15 1990-01-09 Matsushita Electric Ind Co Ltd 超音波変換装置
NZ254550A (en) 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
EP0889034B1 (en) * 1996-03-21 2003-09-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient

Also Published As

Publication number Publication date
DE60123458T2 (de) 2007-08-02
ES2271100T3 (es) 2007-04-16
PT1335906E (pt) 2007-01-31
JP2004524279A (ja) 2004-08-12
MXPA03004136A (es) 2003-08-19
ZA200302970B (en) 2004-07-15
US20020086858A1 (en) 2002-07-04
US6657060B2 (en) 2003-12-02
AU2790502A (en) 2002-05-21
KR100611853B1 (ko) 2006-08-11
EP1335906B1 (en) 2006-09-27
AR034700A1 (es) 2004-03-17
DK1335906T3 (da) 2007-02-05
KR20040004432A (ko) 2004-01-13
ATE340784T1 (de) 2006-10-15
AU2002227905B2 (en) 2006-10-05
EP1335906A1 (en) 2003-08-20
UY27018A1 (es) 2002-06-20
DE60123458D1 (de) 2006-11-09
CA2427350A1 (en) 2002-05-16
CN1473156A (zh) 2004-02-04
PA8531701A1 (es) 2003-06-30
BR0115045A (pt) 2004-02-03
WO2002038551A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
PE20011259A1 (es) Derivado de piridina y pirimidina
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
ES2192264T3 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
TW200734337A (en) Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
PE20081679A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
AR049696A1 (es) Derivados de indol
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal